Tune in as the IMF brings myeloma support group leaders and patients to Orlando, FL for the 61st annual meeting of the American Society of Hematology (ASH), an exciting convergence of 20,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#ASH19 and #IMFASH19), Facebook, blogs, and videos.

Jack Aiello

Follow Jack on Twitter:
@JackMAiello
Read Blog Posts

Sheri Baker

Follow Sheri on Twitter:
@blondie1746
Read Blog Posts

Yelak Biru

Follow Yelak on Twitter:
@NorthTxMSG
Read Blog Posts

Cynthia Chmielewski

Follow Cindy on Twitter:
@MyelomaTeacher
Read Blog Posts

John deFlice

Follow John on Twitter:
@JohnDe1MYELOMA
Read Blog Posts

Linda Huguelet

Follow Linda on Twitter:
@LindaMYELOMA
Read Blog Posts

Teresa Miceli

Follow Teresa on Twitter:
@IMFnurseMYELOMA
Read Blog Posts

Jim Omel

Follow Jim on Twitter:
@IMFjimMYELOMA
Read Blog Posts

Valarie Traynham

Follow Valarie on Twitter:
@MyelomaValarie
Read Blog Posts

Michael Tuohy

Follow Michael on Twitter:
@IMFmikeMyeloma
Read Blog Posts

Robin Tuohy

Follow Robin on Twitter:
@IMFSupport
Read Blog Posts

Tiffany Williams

Follow Tiffany on Twitter:
@MyelomaHope
Read Blog Posts
Recent Blog Posts from ASH 2019
  • That’s a Wrap!

    Sheri Baker |

    The 61st ASH Annual Meeting and Exposition is over. I’m home in Idaho now, and missing the warm sunshine of Orlando. And the warm and friendly camaraderie of the International Myeloma Foundation’s team of support group leaders. I saw many things that amazed me during my first experience at #ASH19. Thousands of people all trying […]

  • Immunotherapy – Front and Center

    Cynthia Chmielewski |

    Immunotherapy was front and center at this year’s American Society of Hematology’s (ASH) meeting. There even was an Education Session presented by Drs. Shah, Cohen and Borello on this topic. When I first attended the ASH Annual Meeting in 2012, immunotherapy was still in its infancy. The treatments that were being examined in clinical trials back […]

  • An Evening of Hope Through Patient Stories and Research

    Robin Tuohy |

    Each year at the American Society of Hematology (ASH) meetings, the International Myeloma Foundation (IMF) presents a program entitled “Living Well with Myeloma and the 2020 Brian D. Novis Grant Awards Reception.”  In 1995 the IMF established the Brian D. Novis Research Grant program in memory of its co-founder. The grants are awarded annually to promote […]

  • Dara, the new Bacon…I mean, Beacon of Myeloma

    Yelak Biru |

    One of the late-breaking abstracts presented by Dr. Saad Usamani compared Kyprodlis and dexamethason (Kd) with Kd and daratumumab. There were many trial results that were presented at ASH that showed Dara makes many drugs better. Combining Dara with KRd seems to result in an “unprecedented” level of response and MRD negative response for newly […]

  • “Don’t Back Down!”

    Michael Tuohy |

    The days of ASH are filled with oral abstracts, posters, education, and scientific sessions—some of which are even simultaneous sessions. It’s a challenge to be everywhere, and I’m thankful that Dr. Durie provides the leaders with his suggestions on what would be most valuable for us to attend. Program for the “Living Well with Myeloma” […]

  • ASH 2019: Summary, Thoughts, and Impressions

    Jim Omel |

    The entryway at #ASH19 Each ASH annual meeting has its own ‘flavor’ and emphasis regarding myeloma. I’ve been to several and remember the excitement of ASH2015 after our unprecedented elotuzumab, daratumumab, Ninlaro, “November to Remember.” Last year the emphasis was on early immunotherapy with BiTEs, CAR-T, and ADCs (antibody drug conjugates). This year ASH2019 was […]

  • The Size of the Dog

    John DeFlice |

    In the words of Mark Twain, “It’s not the size of the dog in the fight but fight in the dog.” We are often so consumed by our bad feelings that we don’t have the energy to deal with the issues that accompany us on our myeloma journey.  When listening to the speakers at the […]

  • Summary of ASH 2019

    Jack Aiello |

    Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early Tuesday morning describing a phase III trial called Candor for relapsed/refractory multiple myeloma patients (RRMM), comparing (Kyprolis) carfilzomib and dexamethasone with or without Darzalex (daratumumab). The abstract #LBA-6 showed that the addition of dara decreased the risk […]

  • It Takes a Village

    Sheri Baker |

    I’ll admit I was a little starstruck at ASH. The top myeloma specialists were gathered in one place, walking the same corridors as me…sitting in the same abstract presentations as me.  And having some of the same questions as I did about the research being presented. I was used to being at patient seminars or my […]

  • It’s All About That Dara, That Dara!

    Valarie Traynham |

    Daratumumab (dara), trade name Darzalex, received breakthrough therapy drug status in 2013 for multiple myeloma. Daratumumab is a monoclonal antibody directed against CD38, a molecule present on myeloma cells. Since it’s inception, it has taken the myeloma world by storm. In late 2015 daratumumab was approved by the U.S. Food and Drug Administration (FDA) for treatment of […]